(Il Sole 24 Ore Radiocor) - Milano, 13 apr - Shares in Spyre Therapeutics surged after the biotechnology company announced "positive" results in a trial of its candidate SPY100 treatment for moderate to severely active ulcerative colitis.

Spyre said it has achieved positive 12-week induction data from the first part of its Phase 2 Skyline trial of SPY001.

"SPY001 was designed to improve upon vedolizumab's proven activity in IBD by matching its epitope and potency while increasing target coverage through an extended half-life and greater induction dosing," Deanna Nguyen, SVP of Clinical Development and SKYLINE study lead, said.

"Our data today support the hypothesis that this approach could lead to a best-in-class anti-47 product across safety, efficacy, and convenience.".

At 1433 GMT Spyre Therapeutics shares were up 25%

(RADIOCOR) 13-04-26 16:34:37 (0463) 5 NNNN